CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today announced data from its first biologic/small molecule combination High Throughput Screening (cHTS™) effort identifying drug classes that synergistically enhance the activity of the oncology-relevant cytokine TNF-related apoptosis inducing ligand (TRAIL) to overcome a common mechanism of TRAIL resistance. These data were presented today in a poster entitled “Synergistic Enhancers of TRAIL-Mediated Apoptosis: A Quantitative Parallel Comparison of TRAIL-Small Molecule Synergies using cHTS™”, Short, et.al, at the 98th Annual Meeting of the American Association for Cancer Research in Los Angeles, CA.
